Published on 29 Feb 2024 on Zacks via Yahoo Finance
Jazz Pharmaceuticals JAZZ reported adjusted earnings of $5.02 per share in fourth-quarter 2023, missing the Zacks Consensus Estimate of $5.26. In the year-ago period, the company reported an adjusted loss of 7 cents per share.
Total revenues in the reported quarter rose 4% year over year to $1.01 billion. Sales of Xywav, Epidiolex and Rylaze drove the upside. Total revenues were in line with the Zacks Consensus Estimate. Per management, this was the first time where the company achieved a billion dollars in quarterly sales.
Jazz’s shares were down 1.5% in after-market trading on Feb 28, likely due to the lower-than-expected earnings reported during the quarter.